It is important to know that compounded GLP-1 products are not reviewed by the FDA, meaning there is less rigorous oversight compared with brand-name products
A 2023 study Trusted Source American Journal of Clinical Nutrition Go to source suggests there is high burden of obesity and other metabolic disorders, including type 2 diabetes, in inflammatory bowel disease (IBD) patients
As a result, some are able to achieve glucose and weight reductions comparable to injectable semaglutide therapy, while others struggle with missed doses and dosing with other medications or food and drink, and thus suboptimal benefits
Everyone responds differently to weight loss treatment and we'll help you find what feels right for you." Weight loss medication If you are thinking of trying weight loss medication, please dont let the above put you off
REF 1593 11/2022 You are encouraged to report adverse drug events (ADEs) to American Regent: T 1.800.734.9236
Let me see the kids